After hours: 4:51PM EDT
|Bid||365.89 x 1300|
|Ask||368.22 x 1000|
|Day's Range||361.99 - 369.37|
|52 Week Range||226.02 - 373.90|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||63.21|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||1.36 (0.38%)|
|1y Target Est||400.00|
WAYNE, Pa., Aug. 21, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo Securities 2019 Healthcare Conference at.
Teleflex Incorporated (TFX) today announced the UroLift® System, a proven, minimally invasive treatment for patients with benign prostatic hyperplasia (BPH), won the 2019 James & Wells Medical Technology Association of New Zealand (MTANZ) Innovation Award at the Health Tech Week Gala on July 2. The MTANZ Innovation Award recognizes products that significantly contribute to improving patient outcomes by enhancing their quality of life, as well as exhibiting technical excellence and innovation across the entire medical device sector. Recipients for the MTANZ Innovation Award are determined by a judging panel consisting of distinguished industry leaders and clinicians.
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 2.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Aug. 01, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per.
Second Quarter Revenues from Continuing Operations of $652.5 million, up 7% versus Prior Year Period; up 9.6% on a Constant Currency Basis Second Quarter GAAP Diluted EPS from.
WAYNE, Pa., Aug. 01, 2019 -- Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the.
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.